BGI Shenzhen Co., Ltd.

DUBLIN--( BUSINESS WIRE )--The "Australia Non-Invasive Prenatal Testing (NIPT) Market: Focus on Technology, Method, Application, and End User - Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering. The Australia non-invasive prenatal testing (NIPT) market, initially valued at $40.0 million in 2023, is set for substantial growth, projected to surge to $110.7 million by 2033, marking a remarkable compound annual growth rate (CAGR) of 10.71% over the period from 2024 to 2033. The base year considered for the calculation of the market size is 2023. A historical year analysis has been done for the period FY2019-FY2022. The market size has been estimated for FY2023 and projected for the period FY2024-FY2033. The Australia non-invasive prenatal testing (NIPT) market shows promising growth, driven by increasing awareness, rising maternal age, and advanced diagnostic technologies. Expanding healthcare access and a preference for non-invasive methods contribute to demand, with potential growth through innovation and competitive pricing strategies. Industrial Impacts The Australia non-invasive prenatal testing (NIPT) market is set for steady growth, driven by broader advancements in diagnostic testing and healthcare services. As healthcare systems evolve, there is a growing emphasis on non-invasive, cost-effective diagnostic solutions, particularly in prenatal care. Technological advancements and the increasing focus on precision medicine are enhancing the accuracy and accessibility of genetic screenings. The expansion of diagnostic capabilities and a rising demand for safer, more reliable testing methods are likely to propel the adoption of non-invasive prenatal testing (NIPT). Increasing maternal age and growing awareness of genetic conditions further contribute to the demand for non-invasive prenatal testing (NIPT). The Australia healthcare system's ongoing improvements, including funding for advanced medical technologies, provide a conducive environment for market growth. Moreover, policy reforms and healthcare initiatives aimed at expanding access to genetic testing in both urban and rural settings are expected to boost market penetration. NGS Technology Segment to Dominate the Australia Non-Invasive Prenatal Testing (NIPT) Market (by Technology) Based on technology, the Australia non-invasive prenatal testing (NIPT) market was led by the NGS technology segment, which held a 54.75% share in 2023. next-generation sequencing (NGS) offers highly accurate, non-invasive genetic screening using a simple maternal blood sample. This technology enables the detection of chromosomal abnormalities, such as trisomies 13, 18, and 21, by analyzing cell-free DNA (cfDNA) fragments from the mother's blood. Non-invasive prenatal testing (NIPT) using NGS works by identifying specific genetic markers within the cfDNA to assess the risk of chromosomal abnormalities in the fetus. The test provides early results, typically within 5-7 days, allowing parents to make informed decisions early in their pregnancy. For instance, Illumina, Inc.'s VeriSeq NIPT Solution v2 is a next-generation sequencing-based non-invasive prenatal testing (NIPT) with approximately 99.9% sensitivity. It is a streamlined, accessible solution that offers clinicians reliable results and enables sample reporting in about 26 hours. cfDNA Segment to Dominate the Australia Non-Invasive Prenatal Testing (NIPT) Market (by Method) Based on the method, the Australia non-invasive prenatal testing (NIPT) testing market was led by the cfDNA method segment, which held an 87.25% share in 2023. Cell-free DNA (cfDNA) testing is a widely used method in Australia's non-invasive prenatal testing (NIPT) market, allowing for the detection of fetal chromosomal abnormalities by analyzing small fragments of fetal DNA in maternal blood. This method offers high accuracy and minimal risk compared to invasive techniques such as amniocentesis. For instance, F. Hoffmann-La Roche Ltd. offers Harmony Test, a prominent offering that utilizes cfDNA technology to screen trisomies 13, 18, and 21 with proven clinical precision. Similarly, Victorian Clinical Genetics Services Limited provides the percept NIPT, leveraging cfDNA to ensure effective early detection of chromosomal anomalies. Healius Limited (Genetic Diagnostics) expands the cfDNA-based offerings with its Generation NIPT, Generation 46, and Generation Plus, which cater to diverse testing needs, including comprehensive assessments for microdeletions and rare genetic conditions. These examples highlight the integral role of cfDNA methods in Australia's non-invasive prenatal testing (NIPT) advancements. Trisomy Detection Segment to Dominate the Australia Non-Invasive Prenatal Testing (NIPT) Market (by Application) Based on application, the Australia non-invasive prenatal testing (NIPT) testing market was led by the trisomy detection application segment, which held a 56.50% share in 2023. Trisomy detection is one of the primary applications of non-invasive prenatal testing (NIPT), focusing on identifying chromosomal abnormalities such as Trisomy 21 (Down Syndrome), Trisomy 18 (Edwards Syndrome), and Trisomy 13 (Patau Syndrome). These conditions occur when there are three copies of a chromosome instead of the normal two, leading to fetal developmental and health complications. For instance, tests offered by Sonic Healthcare, F. Hoffmann-La Roche Ltd., and Healius Limited, among others, namely, percept NIPT, Harmony, and Generation NIPT, offer a highly accurate and reliable method for detecting these trisomies by analyzing cell-free fetal DNA (cffDNA) present in maternal blood. Australia non-invasive prenatal testing (NIPT) market was led by the hospital and clinics segment, which held a 72.25% share in 2023. The dominance of hospitals in the Australia non-invasive prenatal testing (NIPT) market is underscored by their pivotal role in providing comprehensive healthcare services and incorporating non-invasive prenatal testing (NIPT) into their services to enhance the range of prenatal diagnostics offered to expectant parents. This segment involves the utilization of non-invasive prenatal testing (NIPT) technologies within hospital facilities, allowing for efficient and accurate screening of genetic abnormalities in the fetus. Hospitals may also exist in the private sector, owned by for-profit or nonprofit organizations. In the case of private hospitals, funding is sourced from patients' direct payments for medical services, insurance coverage, government support through national health insurance initiatives, or financial assistance from foreign embassies. How can this report add value to an organization? Product/Innovation Strategy: The Australia non-invasive prenatal testing (NIPT) market has been extensively segmented based on various categories, such as technology, method, application, and end user. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years. Growth/Marketing Strategy: Mergers, acquisitions, and product launches accounted for the minimal number of key developments, i.e., nearly 30.61% of the total developments in the Australia non-invasive prenatal testing (NIPT) market were between January 2019 and September 2024. Competitive Strategy: The Australia non-invasive prenatal testing (NIPT) market has numerous established players with product portfolios. Key players in the Australia non-invasive prenatal testing (NIPT) market analyzed and profiled in the study involve established players offering products for Australia non-invasive prenatal testing (NIPT). Key Market Players and Competition Synopsis Victorian Clinical Genetics Services Limited Healius Limited F. Hoffmann-La Roche Ltd Illumina, Inc. Novacyt BGI Genomics Natera, Inc. Monash IVF Group Virtus Health Sonic Healthcare Limited PathWest Laboratory Medicine Key Attributes: Report Attribute Details No. of Pages 70 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $44.3 Million Forecasted Market Value (USD) by 2033 $110.7 Million Compound Annual Growth Rate 10.7% Regions Covered Australia Key Topics Covered: Executive Summary Scope and Definition 1 Markets 1.1 Market Outlook 1.2 Key Findings 1.3 Australia Market Scenario 1.3.1 Realistic Scenario 1.3.2 Optimistic Scenario 1.3.3 Pessimistic Scenario 1.4 Industry Outlook 1.4.1 Trends 1.4.1.1 Expanding Application of Non-Invasive Prenatal Testing (NIPT) Products 1.4.2 Regulatory Landscape 1.4.3 Product Benchmarking 1.5 Business Dynamics 1.5.1 Impact Analysis 1.5.2 Business Drivers 1.5.2.1 High Incidence of Genetic Disorders 1.5.2.2 Rising Maternal Age 1.5.2.3 Rising Adoption of Non-Invasive Prenatal Testing 1.5.3 Business Restraints 1.5.3.1 Lack of Awareness Regarding Non-Invasive Prenatal Testing (NIPT) 1.5.4 Business Opportunities 1.5.4.1 Expansion of NIPT Accessibility and Coverage 2 Australia Non-Invasive Prenatal Testing (NIPT) Market, Test Volume 2.1 Test Volume 3 Australia Non-Invasive Prenatal Testing (NIPT) Market, by Technology 3.1 Opportunity Assessment 3.2 Growth-Share Matrix 3.2.1 NGS 3.2.2 PCR 3.2.3 Others 4 Australia Non-Invasive Prenatal Testing (NIPT) Market, by Method 4.1 Opportunity Assessment 4.2 Growth-Share Matrix 4.2.1 cfDNA 4.2.2 FCMB 5 Australia Non-Invasive Prenatal Testing (NIPT) Market, by Application 5.1 Opportunity Assessment 5.2 Growth-Share Matrix 5.2.1 Trisomy Detection 5.2.2 Microdeletion Detection 5.2.3 Sex Chromosome Aneuploidy Detection 5.2.4 Others 6 Australia Non-Invasive Prenatal Testing (NIPT) Market, by End User 6.1 Opportunity Assessment 6.2 Growth-Share Matrix 6.2.1 Hospital and Clinics 6.2.2 Diagnostic Laboratories 6.2.3 Others 7 Company Profiles 7.1 Overview 7.2 Top Products/Service 7.3 Top Competitors 7.4 Key Personnel 7.5 Analyst View 8 Research Methodology For more information about this report visit https://www.researchandmarkets.com/r/tbu1p1 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

SAN JOSE, Calif., Jan. 9, 2025 /PRNewswire/ -- In 2024, Complete Genomics, a pioneering genomic sequencing company, expanded its U.S. manufacturing footprint with augmented technology capabilities to diversify its supply chain helping it to continue reliably serving customers with flexible, cost-effective next generation sequencing (NGS) solutions. Expanding U.S. manufacturing capabilities in 2024 and beyond After weathering a year of geopolitical conflict which resulted in the failure of the BIOSECURE Act, which was legislation that targeted individual companies under the guise of genetic data security, Complete Genomics opened two facilities in 2024 as part of its localization strategy, establishing its first U.S. supply chain. In May, the company inaugurated a 10,115 square foot manufacturing facility at its San Jose, California headquarters, to provide faster delivery times and reliable local supply assurance for North American customers. Since then, the new San Jose facility has produced DNBSEQ-G99RS* (" G99") low-to-mid-range throughput sequencers, used for targeted gene and small genome sequencing research, which are for their exceptionally fast run time of 12 hours with preliminary reporting available in the first 2.5 hours during PE100 or PE150 sequencing runs. Adding to its list of 2024 manufacturing milestones, Complete Genomics built up its quality assurance function and training program, resulting in its first NRTL (Nationally Recognized Testing Laboratory) certification for its production of G99 in North America. As part of its 2025 roadmap, Complete Genomics will continue to build its reagent production capabilities for its G99 and DNBSEQ-T7RS™* (" T7") sequencing platforms and pursue ISO 13485 certification, a voluntary regulatory quality standard published by the International Organization for Standardization (ISO) for the design and manufacturing of medical devices. "Using the blueprint for manufacturing capabilities around the G99, in the coming year, we plan to bring on the manufacturing of the T7 in the region, further cementing our strategy for local manufacturing in the United States" said Rob Tarbox, VP of Product and Marketing at Complete Genomics. In addition to the new San Jose facility, Complete Genomics expanded to the East Coast with the opening of a second Customer Experience Center (CEC) in Framingham, near Boston's biotech hub. The demonstration lab, which opened in May 2024, allows current and prospective customers to experience Complete Genomics' DNBSEQ™ workflows, including next-generation sequencing platforms, sample prep automation systems, and bioinformatics products. Strategic Partnerships and Collaborations Throughout 2024, Complete Genomics forged several key collaborations to enhance its offerings and expand its reach, including collaborations with NVIDIA, Eurofins Clinical Enterprise, AdvancedDx Biological Laboratories USA Inc., and seqWell. The collaboration with NVIDIA integrated NVIDIA Parabricks to offer researchers faster, more effective and accurate genomic sequencing analysis, leveraging NVIDIA's expertise in AI and accelerating computing. The seqWell collaboration expanded the range of library preparation product offerings to Complete Genomics customers, ensuring seqWell-developed products are compatible with the entire Complete Genomics NGS and automation portfolios. The agreement with AdvancedDx Biological Laboratories USA Inc., enabled the combination of AdvanceDX Biological Laboratories USA Inc's DeepChek® assays and software with Complete Genomics' DNBSEQ platforms to all microbiology laboratories in the U.S. Complete Genomics added Framingham, Massachusetts-based Eurofins Clinical Enterprise, LLC, as the newest addition to its Sequencing Service Provider Program, which connects its customers to a network of service providers, offering access to high-quality sequencing services using its DNBSEQ platforms. Product Innovation and Expansion Complete Genomics continued to innovate and expand its product portfolio in 2024: The company expanded its multi-omics and spatial transcriptomics applications, showcasing these innovations at the American Society of Human Genetics (ASHG) 2024 Annual Meeting, unveiling The Complete Genomics Spatial Xcellerator Grant Program was announced at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Conference, promoting advancements in spatial omics research as the exclusive U.S. distributor of STOmics' Stereo-seq technology for spatial transcriptomics. The company celebrated product launches and upgrades, enrolled new spatial certified service providers, and expanded user accessibility in spatial transcriptomics. The company introduced the mpox virus amplicon sequencing panel, addressing the need for advanced tools in infectious disease research. Looking Ahead Dr. Radoje Drmanac, Founder and Chief Scientific Officer of Complete Genomics, commented on the year's achievements: "It has been a transformative year for Complete Genomics. Our expansion in manufacturing and customer support, coupled with strategic collaborations and product innovations, positions us strongly for continued growth in the genomics field. We remain committed to advancing high-throughput, cost-effective sequencing technologies to support groundbreaking research and clinical applications, solidifying its position as a leader in genomic sequencing technology." About Complete Genomics Complete Genomics is a pioneering life sciences company that provides novel, end to end DNA sequencing solutions. It has been at the forefront of high throughput cost-effective sequencing technology development since its inception in 2005. Our products have powered over 9,400 publications across a wide array of applications. To learn more, visit . Media Contact: Betsy Yates Complete Genomics [email protected] SOURCE Complete Genomics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

FRAMINGHAM, Mass., Dec. 17, 2024 /PRNewswire/ -- Complete Genomics, a San Jose, California based genomics tools manufacturer, today announced Framingham, Massachusetts based Eurofins Clinical Enterprise, LLC as the newest addition to its Sequencing Service Provider Program. Complete Genomics' Service Provider Program connects its customers to a network of service providers, offering access to high-quality sequencing services using Complete Genomics DNBSEQ™ sequencing platforms. As part of the partnership, Eurofins Clinical Enterprise will use the DNBSEQ-T7RS™* ("T7"), Complete Genomics' flagship sequencer, to perform whole genome sequencing, low-pass whole genome sequencing (lpWGS), spatial-resolved transcriptomics, and single-cell sequencing. The Eurofins Clinical Enterprise team expressed their enthusiasm about utilizing the T7 to enhance the company's flexibility in handling a wide range of research project sizes, while maintaining competitive pricing and quick turnaround times. "This partnership is another way that Complete Genomics and its partners are expanding what is possible while also lowering costs and turnaround time for our customers," said Rob Tarbox, VP of Product and Marketing at Complete Genomics. About Complete Genomics Complete Genomics is a pioneering life sciences company that provides novel, end to end DNA sequencing solutions. It has been at the forefront of high throughput cost-effective sequencing technology development since its inception in 2005. Our products have powered over 9,400 publications across a wide array of applications. To learn more, visit . * For Research Use Only. Not for use in diagnostic procedures. About Eurofins Clinical Enterprise, LLC Eurofins Clinical Enterprise is engineered for integration and powered for collaboration. As an advanced, CLIA-certified, CAP-accredited, NY CLEP-licensed multiomic services laboratory, we provide customizable data integrations and fast, accurate testing at competitive prices. Clinical Enterprise strives to build bridges to discovery in academic research, biopharma uses, clinical studies, lifestyle genomics, and more. Eurofins Scientific through its subsidiaries is a world leader in food, environment, pharmaceutical and cosmetic product testing, discovery pharmacology, forensics, advanced material sciences, and agroscience contract research services. To learn more, visit SOURCE Complete Genomics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED